Home › Compare › MEDIF vs ORCC

MEDIF vs ORCC: Dividend Comparison 2026

MEDIF yields 4345.46% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEDIF wins by $15969693446288.77M in total portfolio value
10 years
MEDIF
MEDIF
● Live price
4345.46%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15969693446288.79M
Annual income
$15,278,069,441,942,714,000.00
Full MEDIF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — MEDIF vs ORCC

📍 MEDIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEDIFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEDIF + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MEDIF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDIF
Annual income on $10K today (after 15% tax)
$369,364.48/yr
After 10yr DRIP, annual income (after tax)
$12,986,359,025,651,306,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, MEDIF beats the other by $12,986,359,025,651,306,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDIF + ORCC for your $10,000?

MEDIF: 50%ORCC: 50%
100% ORCC50/50100% MEDIF
Portfolio after 10yr
$7984846723144.41M
Annual income
$7,639,034,720,971,357,000.00/yr
Blended yield
95.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

MEDIF
No analyst data
Altman Z
-2.9
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDIF buys
0
ORCC buys
0
No recent congressional trades found for MEDIF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEDIFORCC
Forward yield4345.46% ✓9.79%
Annual dividend / share$2.00 ✓$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0% ✓-50%
Portfolio after 10y$15969693446288.79M ✓$21.4K
Annual income after 10y$15,278,069,441,942,714,000.00 ✓$1.04
Total dividends collected$15922667488789.34M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: MEDIF vs ORCC ($10,000, DRIP)

YearMEDIF PortfolioMEDIF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$445,246$434,546.44$11,190$489.61+$434.1K → MEDIF
2$18,558,681$18,082,267.04$12,229$256.01+$18.55M → MEDIF
3$724,251,944$704,394,155.22$13,216$130.74+$724.24M → MEDIF
4$26,465,566,588$25,690,617,008.13$14,207$66.02+$26465.55M → MEDIF
5$905,687,152,836$877,368,996,586.58$15,234$33.17+$905687.14M → MEDIF
6$29,029,592,495,582$28,060,507,242,048.22$16,317$16.62+$29029592.48M → MEDIF
7$871,632,797,918,927$840,571,133,948,653.80$17,468$8.32+$871632797.90M → MEDIF
8$24,520,223,407,609,444$23,587,576,313,836,190.00$18,695$4.16+$24520223407.59M → MEDIF
9$646,377,574,155,211,500$620,140,935,109,069,400.00$20,006$2.08+$646377574155.19M → MEDIF
10$15,969,693,446,288,792,000$15,278,069,441,942,714,000.00$21,407$1.04+$15969693446288.77M → MEDIF

MEDIF vs ORCC: Complete Analysis 2026

MEDIF — Stock

MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.

Full MEDIF Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this MEDIF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDIF vs SCHDMEDIF vs JEPIMEDIF vs OMEDIF vs KOMEDIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.